Benefit-Risk Balance of Reoperation for Persistent Medullary Thyroid Cancer
Authors:
- Andreas MachensAMAndreas Machens
- Henning DralleHDHenning Dralle
- 1 April 2013
- journal article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 257 (4) , 751-757
Abstract
This investigation aimed at exploring the prospects of a cure for persistent medullary thyroid cancer (MTC) stratified by basal calcitonin levels before reoperation and the number of lymph node metastases previously removed at outside facilities. There is no evidence-based information supporting the balance of surgical benefit and risk in persistent MTC. This retrospective study of 334 patients with persistent MTC referred to a tertiary surgical center, who were compared with 367 patients with previously untreated MTC referred to that institution during the same time period, evaluated biochemical cure rates after systematic lymph node dissection. The relationship between the incremental serum calcitonin level before reoperation and the number of lymph node metastases at reoperation and biochemical cure was strong after previous removal of 0 (r = 0.74 and 77%-0%) and 1 to 5 lymph node metastases (r = 0.61 and 60%-0%) elsewhere. It disappeared once more than 5 lymph node metastases had been cleared at other hospitals (nonsignificant and 5%). When serum calcitonin levels were 1000 pg/mL or lower before reoperation, biochemical cure rates were 44% (59 of 133 patients) and 18% (12 of 65 patients) after previous removal of 0 and 1 to 5 lymph node metastases, respectively. These rates plummeted to 5% (2 of 43 patients) after a previous clearance of more than 5 lymph node metastases. When serum calcitonin levels exceeded 1000 pg/mL before reoperation, a biochemical cure was exceptional (1%; 1 of 76 patients). With serum calcitonin levels of 1000 pg/mL or lower before reoperation and the previous removal of 5 or fewer lymph node metastases, systematic lymph node dissection seems worthwhile for persistent MTC. These findings will need to be validated in independent series before being adopted more widely as a new standard of care.Keywords
This publication has 16 references indexed in Scilit:
- Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinomaSurgery, 2011
- American Thyroid Association Guidelines for Management of Medullary Thyroid Cancer: An Adult Endocrinology PerspectiveThyroid®, 2009
- Measurement of calcitonin by immunoassay analyzersClinical Chemistry and Laboratory Medicine (CCLM), 2007
- Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin LevelThe Journal of Clinical Endocrinology & Metabolism, 2005
- Role of preoperative ultrasonography in the surgical management of patients with thyroid cancerSurgery, 2003
- Rationale for Central and Bilateral Lymph Node Dissection in Sporadic and Hereditary Medullary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2003
- Lymph node dissection and medullary thyroid carcinomaBritish Journal of Surgery, 2002
- Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomasSurgery, 2001
- Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysisCancer, 2000
- Primary hereditary medullary thyroid carcinoma - C-cell morphology and correlation with preoperative calcitonin levelsVirchows Archiv, 1998